PVLA — Palvella Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Pieris Pharmaceuticals Inc Received Notice Of Delisting From Nasdaq
Pieris Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Pieris Pharmaceuticals Reports Q1 Results
Pieris Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Pieris Pharmaceuticals falls on lower Q4 revenue
Pieris Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Pieris Pharmaceuticals Reports FY 2022 Net Loss Of $0.45 Per Share
Pieris Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Pieris Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Pieris Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Pieris Pharmaceuticals Reports Quarterly Loss Per Share Of $0.13 - Filing
Brief: Pieris Pharmaceuticals Announces Dosing Of First Subject In Phase 1 Trial Of Inhaled Ctgf Inhibitor PRS-220
Pieris Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Pieris Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pieris Pharmaceuticals Says Quarterly Net Loss Was $10.3 Mln
Pieris Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Pieris Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Pieris Pharmaceuticals Inc - Net Loss Was $5.1 Million Or $0.07 Per Share For The Quarter Ended March 31, 2022
Pieris Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview